Akari Therapeutics Management
Management criteria checks 1/4
Akari Therapeutics' CEO is Abizer Gaslightwala, appointed in Apr 2025, has a tenure of less than a year. directly owns 0.63% of the company’s shares, worth $239.49K. The average tenure of the management team and the board of directors is 0.3 years and 0.5 years respectively.
Key information
Abizer Gaslightwala
Chief executive officer
US$1.8k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.6% |
| Management average tenure | less than a year |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Akari Therapeutics GAAP EPS of $0.00
Sep 27Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely?
Sep 20
Akari Therapeutics announces positive results from pre-clinical studies of eye disease treatment
Jul 28Akari Therapeutics GAAP EPS of $0.00
Jul 20Patient completes course with Akari's stem cell transplant related complication treatment
Jul 07We're Keeping An Eye On Akari Therapeutics' (NASDAQ:AKTX) Cash Burn Rate
Dec 31We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully
Mar 15Do Institutions Own Akari Therapeutics, Plc (NASDAQ:AKTX) Shares?
Jan 21Read This Before Selling Akari Therapeutics, Plc (NASDAQ:AKTX) Shares
Dec 17CEO
Abizer Gaslightwala (50 yo)
less than a year
Tenure
US$1,796
Compensation
Mr. Abizer Gaslightwala has been President & CEO of Akari Therapeutics Plc since April 21, 2025 and serves as its Independent Director. He was Director of Akari Therapeutics Plc from December 16, 2024. Mr....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$1.80k | 0.63% $ 239.5k | |
| Chief Financial Officer | less than a year | US$290.70k | 0.0014% $ 529.8 | |
| Chief Scientific Officer | no data | no data | no data | |
| Executive Director & Head of Oncology | 2.5yrs | no data | no data | |
| Head of Business Development - Oncology | no data | no data | no data |
0.3yrs
Average Tenure
54yo
Average Age
Experienced Management: AKTX's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$1.80k | 0.63% $ 239.5k | |
| Independent Director | less than a year | US$185.13k | 1.93% $ 734.9k | |
| Independent Director | less than a year | US$21.63k | 0.15% $ 58.9k | |
| Independent Director | less than a year | US$228.64k | 0.071% $ 27.2k | |
| Independent Chairman | less than a year | US$543.63k | 16.64% $ 6.3m | |
| Independent Director | 9.7yrs | US$103.91k | 8.67% $ 3.3m | |
| Director | 1.5yrs | US$462.14k | 10.65% $ 4.1m |
0.5yrs
Average Tenure
56yo
Average Age
Experienced Board: AKTX's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/16 22:09 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Akari Therapeutics, Plc is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Madhu Kumar | B. Riley Securities, Inc. |
| Arlinda Lee | Canaccord Genuity |